Figure 2. Ten days after admission, showing widespread skin infarction Discussion
Meningococcal endotoxin has the capacity to act on skin vessels, causing activation of complement and clotting factors, and leading to disseminated intravascular coagulation (DIC) with resulting depletion of clotting factors. In purpura fulminans, endothelial cell injury is followed by fibrin deposition, and unlike the primary meningococcal emboli which are arteriolar, these fibrin deposits are mainly capillary and venous, and lead to extensive ecchymoses and infarction of the skin 1.2. The lower limbs and buttocks are especially likely to need grafting".
The currently accepted management. of disseminated intravascular coagulation is to treat the underlying cause and replace clotting factors", This policy assumes that the underlying cause can be swiftly removed, but antibiotic treatment of meningococcal septicaemia does not destroy or remove the cause of the DIC, namely endotoxin. Thus, DIC complicating meningococcal septicaemia constitutes an important indication for the use of heparin", It is possible that the more prompt use of heparin in our case might have reduced the widespread skin infarction which developed during the first 12 h in hospital. Case report An ll-year-old boy presented with sudden onset of a widespread purpuric rash following an upper respiratory tract infection. On arrival at the local hospital a diagnosis of meningococcal septicaemia was made. A coagulation study on admission showed a reduced platelet count (llOx 10 9 /1), a prothrombin time of 32 s (control 16 s), a partial thromboplastin time of 46 s (control 31 s) and a plasma fibrinogen of 1.25 gil (normal range 1.5-4.0 gil). He was immediately given intravenous benzyl penicillin 2 million units, chloramphenicol 1 g, gentamicin 40 mg. Because of the rapid progression of his purpuric rash, which became confluent over large areas of skin (purpura fulminans), fresh frozen plasma (FFP) was infused at a rate of 100 ml/kg/24 h, and he was transferred to Booth Hall Children's Hospital for intensive care. On admission he was treated with intravenous penicillin 300 000 units/kg/ day, sulphadimidine 100 mg/kg/day and chloramphenicol 100 mg/kg/day, hydrocortisone succinate 100 mg as a bolus and then 25 mg/h, phenobarbitone 60 mg twice daily and FFP at 50 ml/kg/24 h. Figure 1 . Results ofhaematological investigations before, during and after heparin therapy Leg ulcers secondary to vasculitis in rheumatoid arthritis are notoriously dificult to heal. We report a case that responded to low dose intermittent oral methotrexate therapy.
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Case report
A 58-year-old woman with a 12 year history of seropositive rheumatoid arthritis developed painful ulceration of both legs at the age of 54. Penicillamine (1 g daily for one year), gold injections and minocycline 100 mg twice a day had been used without benefit.
Examination revealed classical rheumatoid arthritis, rheumatoid nodules on the elbows and backs of the hands and painful nail fold infarctions. The ulcers were extensive and deep, (down to tendon) and had a punched out, tender margin. Sensation and peripheral pulses were normal, and varicose veins were not present.
Investigations revealed a raised erythrocyte sedimentation rate of 96 mm/h (Westerpen method), and a very high titre of rheumatoid factor (1 in 512O-modified Rose-Waaler assay).
Anti-nuclear factor was raised at a titre of 1 in 640 (homogenous pattern), and circulating immune complexes were also raised (modified Raji cell assay). Haemoglobin, protein electrophoresis, serum zinc, complement levels, cryoglobulins, DNA binding, i n d syphilis serology were all normal.
A skin biopsy taken from the margin of a typical ulcer showed a v d i t i s with fibrinoid necrosis of the vessel walls. These changes were not considered to be secondary to the ulceration as they extended well away from the ulcer margin. Direct immunofluorescence of perilesional skin showed deposits of C3 in the dermal blood vessels. Four months of intensive conservative management 88 an inpatient failed to improve the ulcers, and in addition, the immobility associated with prolonged bed rest resulted in a deterioration of the patient's joint stiffness.
Oral methotrexate was initiated (10 mg weekly), and after 5 weeks therapy the ulcers started to reduce in size and depth. Complete healing of the right leg was noted at 4 months (Figure I) , and at 6 months for the left leg. The patient is now mobile and has no pain from the ulcers, although her joint symptoms and serological abnormalities have remained unchanged despite treatment.
Discussion
Our patient's clinical and serological findings suggest that she has rheumatoid arthritis with vasculitis. Although ulcerated rheumatoid noduleg, neuropathy, pyoderma gangrenosum3 and stasis4 secondary to immobility can all contribute to the refractory nature of leg ulceration in rheumatoid Case presented to Section of Dermatology, 19 January 1989
Figure 1. Right ankle showing complete healing of vasculitic ulcers in apatient with rheumatoid arthritis following4 months of low dose weekly oral methotrexate
arthritis, none of these factors appeared to play a major role in our patient's ulcers.
Reduction in pain was the first benefit from methotrexate therapy to be noted in our patient, and it allowed the patient to be followed up as a n outpatient, thereby avoiding the morbidity and high cost associated with hospital admission. Methotrexate has been used in the treatment of joint symptoms in rheumatoid arthritis as early as 19516, and recent controlled studies'J suggest it has a role in the treatment of synovitis unresponsive to other therapies. The use of oral methotrexate for cutaneous vasculitic ulceration associated with rheumatoid arthritis was first suggested by Espinoza et aL2 although its mode of action is unclear. They treated eight patients who had longstanding vasculitic ulcers unresponsive to other immunosuppressive therapy with once weekly oral methotrexate (in doses up to 20 mg), and resolution of the ulcers was noted at about 12 weeks of therapy. This report suggests that low dose oral methotrexate therapy may be a useful treatment for refractory cases of vasculitic cutaneous ulceration in rheumatoid arthritis, which in addition has the potential advantage of benefiting other manifestations of the disease.
